{"id":"NCT02787551","sponsor":"Sanofi","briefTitle":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","officialTitle":"A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-06","primaryCompletion":"2018-05-25","completion":"2018-11-17","firstPosted":"2016-06-01","resultsPosted":"2019-06-12","lastUpdate":"2022-03-25"},"enrollment":514,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Insulin glargine/lixisenatide fixed ratio combination","otherNames":["HOE901/AVE0010","Soliqua"]},{"type":"DRUG","name":"liraglutide","otherNames":["Victoza"]},{"type":"DRUG","name":"exenatide","otherNames":["Byetta"]},{"type":"DRUG","name":"exenatide extended-release","otherNames":["Bydureon"]},{"type":"DRUG","name":"albiglutide","otherNames":["Tanzeum"]},{"type":"DRUG","name":"dulaglutide","otherNames":["Trulicity"]},{"type":"DRUG","name":"Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)","otherNames":[]}],"arms":[{"label":"Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)","type":"EXPERIMENTAL"},{"label":"GLP-1 Receptor Agonist","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\nTo demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change.\n\nSecondary Objectives:\n\nTo compare the overall efficacy and safety of the insulin glargine/lixisenatide FRC to GLP-1 RA on top of metformin (with or without pioglitazone, with or without sodium-glucose co-transporter 2 \\[SGLT2\\] inhibitor) in participants with type 2 diabetes.\n\nTo evaluate safety, efficacy and other endpoints of FRC up to the end of the extension period.","primaryOutcome":{"measure":"Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26: Core Period","timeFrame":"Baseline, Week 26","effectByArm":[{"arm":"Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)","deltaMin":-1.02,"sd":0.048},{"arm":"GLP-1 Receptor Agonist","deltaMin":-0.38,"sd":0.048}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":19},"locations":{"siteCount":124,"countries":["United States","Canada","Estonia","Germany","Israel","Italy","Romania","Slovakia","Spain"]},"refs":{"pmids":["35332216","35257461","34894329","33468520","31530665"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":255},"commonTop":["Nasopharyngitis","Nausea","Diarrhoea","Upper Respiratory Tract Infection","Influenza"]}}